Jana Nabki
YOU?
Author Swipe
View article: Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project
Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project Open
Introduction The TRIANGLE trial (Dreyling et al, Lancet 2024) compared three treatment arms in untreated, younger patients with mantle cell lymphoma (MCL): arm I (IR-CHOP/R-DHAP + ibrutinib maintenance [Im]), arm A+I (IR-CHOP/R-DHAP + ASCT…
View article: Clinical impact of untargeted baseline plasma metabolomics in newly diagnosed diffuse large B-cell lymphoma
Clinical impact of untargeted baseline plasma metabolomics in newly diagnosed diffuse large B-cell lymphoma Open
Introduction . Metabolomics is emerging as a promising tool to identify novel prognostic biomarkers in hematological malignancies, by capturing not only tumor-related but also host-related clues. However, its prognostic impact in diffuse l…
View article: Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma Open
Early identification of relapsing/refractory diffuse large B-cell lymphoma (DLBCL) represents an unmet clinical need. A real-life cohort of newly diagnosed DLBCL (n = 120) treated with R-CHOP was investigated. Using the standardized uptake…
View article: Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels
Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels Open
Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77 DLBCL cases with both ctDNA and ti…